Capital Genomix, founded in 2000 in Gaithersburg, MD, possesses two powerful and proprietary genomic and proteomic drug development technology platforms. Capital Genomix intends to couple these platforms – GeneSystem320™ (GS320™) for analytical study of genes and gene expression and ImmunoMouse™ for the development of specific antibodies against genetic sequences of biological significance – into a unified, end-to-end gene discovery, functional analysis and target validation system.